Priority Research Papers:
Absence of ERK5/MAPK7 delays tumorigenesis in Atm-/- mice
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1965 views | HTML 2797 views | ?
Abstract
Alba Granados-Jaén1,*, Maria Angulo-Ibáñez1,*, Xavier Rovira-Clavé1, Celina Paola Vasquez Gamez2, Francesc X. Soriano1, Manuel Reina1 and Enric Espel1
1 Celltec-UB, Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, Spain
2 Servei d’Anatomia Patològica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
* These authors have contributed equally to this article
Correspondence to:
Enric Espel, email:
Manuel Reina, email:
Keywords: thymic lymphoma, DNA damage response, γH2AX, BMK1, thymocyte
Received: February 25, 2016 Accepted: October 13, 2016 Published: October 25, 2016
Abstract
Ataxia-telangiectasia mutated (ATM) is a cell cycle checkpoint kinase that upon activation by DNA damage leads to cell cycle arrest and DNA repair or apoptosis. The absence of Atm or the occurrence of loss-of-function mutations in Atm predisposes to tumorigenesis. MAPK7 has been implicated in numerous types of cancer with pro-survival and pro-growth roles in tumor cells, but its functional relation with tumor suppressors is not clear. In this study, we show that absence of MAPK7 delays death due to spontaneous tumor development in Atm-/- mice. Compared with Atm-/- thymocytes, Mapk7-/-Atm-/- thymocytes exhibited an improved response to DNA damage (increased phosphorylation of H2AX) and a restored apoptotic response after treatment of mice with ionizing radiation. These findings define an antagonistic function of ATM and MAPK7 in the thymocyte response to DNA damage, and suggest that the lack of MAPK7 inhibits thymic lymphoma growth in Atm-/- mice by partially restoring the DNA damage response in thymocytes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12908